That might have been a reasonable strategy but expensive and beyond their capacity. Still is.
CE mark should have been delivered last year. It may be that they have been surprised by the new clinical standards, but they shouldn't have been. However, reading between the lines in general, I suspect that it has been harder overall to get a CE mark lately. Especially for non-EU applicants, and I'll include UK in that group now. So, if it's given, it may actually be worth more than it used to be.
What I'd like is an estimate of valuation with a CE Mark and a US partner.
And - I don't understand why the CE Mark should delay a US partnership.
That might have been a reasonable strategy but expensive and...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.010(0.93%) |
Mkt cap ! $20.14M | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.08 | $1.06 | $16.77K | 15.64K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 6725 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.08 | 11531 | 2 |
View Market Depth
| Last trade - 16.10pm 31/07/2025 (20 minute delay) ? |
| OSL (ASX) Chart |